Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Private Advisor Group LLC

Private Advisor Group LLC decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 10.7% during the 3rd quarter, Holdings Channel.com reports. The fund owned 1,767 shares of the medical research company’s stock after selling 211 shares during the period. Private Advisor Group LLC’s holdings in Charles River Laboratories International were worth $348,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Oregon Public Employees Retirement Fund lifted its stake in Charles River Laboratories International by 1.0% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company’s stock worth $914,000 after acquiring an additional 45 shares in the last quarter. American Trust lifted its stake in Charles River Laboratories International by 5.9% during the 2nd quarter. American Trust now owns 976 shares of the medical research company’s stock worth $202,000 after acquiring an additional 54 shares in the last quarter. Tortoise Investment Management LLC lifted its stake in Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after acquiring an additional 57 shares in the last quarter. OLD National Bancorp IN raised its position in Charles River Laboratories International by 3.1% in the 3rd quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock valued at $392,000 after purchasing an additional 59 shares in the last quarter. Finally, Mitchell & Pahl Private Wealth LLC raised its position in Charles River Laboratories International by 2.0% in the 2nd quarter. Mitchell & Pahl Private Wealth LLC now owns 3,154 shares of the medical research company’s stock valued at $652,000 after purchasing an additional 62 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on CRL. Barclays reduced their price target on Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 8th. Baird R W lowered Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 8th. Redburn Atlantic began coverage on Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 price target on the stock. Evercore ISI lowered Charles River Laboratories International from an “outperform” rating to an “inline” rating and reduced their price target for the company from $225.00 to $190.00 in a research report on Monday, October 7th. Finally, Bank of America lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating and reduced their price target for the company from $250.00 to $215.00 in a research report on Wednesday, October 2nd. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $209.00.

Charles River Laboratories International Trading Up 3.5 %

NYSE:CRL opened at $188.90 on Wednesday. The stock’s 50 day moving average price is $193.28 and its 200 day moving average price is $208.83. The company has a market capitalization of $9.75 billion, a PE ratio of 22.24, a P/E/G ratio of 6.20 and a beta of 1.38. The company has a quick ratio of 1.21, a current ratio of 1.58 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 52-week low of $166.87 and a 52-week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.39 by $0.41. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.03 billion. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. On average, research analysts anticipate that Charles River Laboratories International, Inc. will post 10.01 EPS for the current year.

Charles River Laboratories International declared that its board has initiated a share repurchase program on Wednesday, August 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy up to 9.6% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).